findmyKOL

Patrick Ott, MD

Enriched profile

Professor of Medicine, Harvard Medical School; Clinical Director, Melanoma Disease Center; Director, Clinical Sciences, Center for Immuno-Oncology; Senior Physician, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyMedical OncologyFocusCancer Immunotherapy and Biomarkers+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2018–2026

Patrick Ott is Professor of Medicine, Harvard Medical School; Clinical Director, Melanoma Disease Center; Director, Clinical Sciences, Center for Immuno-Oncology; Senior Physician, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 616 publications with 41,494 citations (h-index 82); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Patrick A. Ott, MD, is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute, Boston, MA. The public record shows 616 publications with 41,494 citations (h-index 82), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune cells in cancer. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 12 companies, 1 NIH-funded awards (2018–2026).

  • Most recent indexed publication: 2026 · Nature biotechnology
  • Top research focus: Cancer Immunotherapy and Biomarkers
  • 8 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 12 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Melanoma6 trialsKidney Cancer / RCC1 trialKidney Neoplasms1 trialMultiple Sclerosis1 trialRheumatoid Arthritis1 trialPsoriasis / Psoriatic Arthritis1 trialLupus (SLE)1 trialIBD (Crohn's / UC)1 trialCrohn Disease1 trialColitis, Ulcerative1 trialST Elevation Myocardial Infarction1 trialAutoimmune Diseases1 trialScleroderma, Systemic1 trialSjogren's Syndrome1 trialUlcer1 trialMyositis1 trialDermatomyositis1 trialColitis1 trialErythema1 trialBreast Cancer1 trialLung Cancer (NSCLC/SCLC)1 trialHead & Neck Cancer1 trialLymphoma1 trialHodgkin Disease1 trialSmall Cell Lung Carcinoma1 trialCarcinoma, Squamous Cell1 trial

Research focus

OpenAlex concept fingerprint
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancerCAR-T cell therapy researchMelanoma and MAPK Pathways

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments14Publications4Opdivogeneric · NivolumabClinical trials—Industry payments1Publications10IpilimumabClinical trials1Industry payments—Publications8Braftovigeneric · EncorafenibClinical trials—Industry payments2Publications—Mektovigeneric · BinimetinibClinical trials—Industry payments2Publications—Enhertugeneric · TrastuzumabClinical trials—Industry payments1Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments1Publications—NeoVaxClinical trials1Industry payments—Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments61F. Hoffmann-La Roche AGClinical trials—Industry payments9Abbvie Inc.Clinical trials—Industry payments4Array Biopharma IncClinical trials—Industry payments2Dana-Farber Cancer InstituteClinical trials2Industry payments—National Cancer Institute (NCI)Clinical trials2Industry payments—Patrick Ott, MD, PhDClinical trials2Industry payments—Pfizer Inc.Clinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1Compass TherapeuticsClinical trials1Industry payments—E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments1Eisai Inc.Clinical trials—Industry payments1F. Stephen Hodi, MDClinical trials1Industry payments—Foundation Medicine, Inc.Clinical trials—Industry payments1GlaxoSmithKline, LLC.Clinical trials—Industry payments1Merck Sharp & Dohme CorporationClinical trials—Industry payments1Servier Pharmaceuticals LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
616publications

Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.

41,494citations

Total citations across indexed works.

82h-index

Hirsch index (OpenAlex). i10-index 206.

Clinical & industry

trials, payments and federal funding
8clinical trials

Investigator role on registered studies.

View trials ↓
12companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2018–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:

All 8 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 19 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

Updated 14 Oct 2026

1 NIH research award on record, funded 2018–2026 per NIH RePORTER. The latest:

All 6 award records: search, sort and filter.Explore →

Congress activity

Updated 14 Oct 2026

97 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

All 97 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 18 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    An immunogenic personal neoantigen vaccine for patients with melanoma
    2,931 citations2017
    doi.org ↗
  2. 02
    Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
    2,764 citations2015
    doi.org ↗
  3. 03
    Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
    2,349 citations2018
    doi.org ↗
  4. 04
    A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
    1,459 citations2018
    doi.org ↗
  5. 05
    Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
    1,438 citations2018
    doi.org ↗
All 616 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Genevieve M. Boland192Ryan J. Sullivan185Omid Hamid178Kenneth F. Grossmann173Hussein A. Tawbi168Jennifer A. Wargo167Justin Fairchild167Nathan Hicks166Christine N. Spencer166Jennifer R. Wortman166Brian Weiner166Elizabeth M. Burton166John Auniņš166Christopher R. Cabanski166Julie Densmore166Christopher P. Loo166Farah A. Alayli166Theresa LaVallee166Matthew R. Henn165Nadim J. Ajami165Matthew C. Wong165Ashish Damania165Michael T. Tetzlaff165Shikha Gautam165Christopher McChalicher165Yongwoo David Seo165Christine B. Peterson165Emily Walsh164F. Stephen Hodi135Isabella C. Glitza133Anita Giobbie‐Hurder67Charles H. Yoon55Anna C. Pavlick51Elizabeth I. Buchbinder48Scott J. Rodig46Michael P. Manos46Johanna C. Bendell39Eliezer M. Van Allen35Jerome Ritz34Heather Daley34

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/patrick-ott-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/dana-farber-cancer-institute_melanoma-vaccine-progress-and-possibility-activity-7158156922917982209-QVml

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certification

    Medical Oncology

    2008
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Board Certification

    Internal Medicine

    2005
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • MD

    PhD - Ludwig Maximilians University of Munich, Germany

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
  • Residency

    Internal Medicine - Case Western Reserve University

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
  • Fellowship

    Hematology-Oncology - New York University School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗

Editorial & leadership roles

journal and society appointments
  • Principal Investigator

    first-in-human personalized neoantigen vaccine (NeoVax) trial in melanoma

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
  • Member

    ASCO, AACR, ESMO, SITC (professional/society memberships)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Attending Physician

    Department of Medicine, Brigham and Women's Hospital, Boston, MA

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
  • Director

    Center for Cancer Vaccines, Dana-Farber Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • IND holder of NeoVax (personalized neoantigen vaccine program)
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Member

    Parker Institute for Cancer Immunotherapy network

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →parkerici.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.